Cogent Biosciences Stock (NASDAQ:COGT), Trade Ideas

Cogent Biosciences

Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with strong dependence on oncogenic KIT signaling.

News

Penny Stocks

Small Cap

Pre-Market Outlook

Markets

Movers

Trading Ideas

COGT

MRNS

NMRA

PSNY

RARE

RDZN

TRMD

U.S. stock futures were higher this morning, with the Dow futures gaining over 200 points on Monday.

Marinus Pharmaceuticals, Neumora Therapeutics And Other Big Stocks Moving Lower In Monday&#39;s Pre-Market Session

Intraday Update

ABNB

AKAM

ALSN

ANGI

AZTR

BGLC

BLNK

CART

CCTG

CEVA

CLNN

CNVS

COIN

DTSS

EEIQ

ELWS

ENGN

GLDD

GMBL

HCSG

HOOD

Inspira Technologies Oxy BHN Ltd Ordinary Shares

IINN

IREN

KTOS

Larimar Therapeutics, Inc. - Common Stock

LRMR

LYFT

MGOL

NUKK

QDEL

QRTEB

REZI

SNTG

Sony Group Corporation American Depositary Shares

SONY

SUNW

TSEM

UFCS

UPST

VBIV

Shares of  Sony Group Corporation (NYSE: SONY) fell during Wednesday’s session after the company reported third-quarter financial results and revised guidance above estimates and shared plans to list its financial arm in October 2025.

Why Sony Shares Are Trading Lower By Around 6%? Here Are Other Stocks Moving In Wednesday&#39;s Mid-Day Session

Earnings

Eurozone

Commodities

Global

KTTA

Morgan Stanley Capital Protected Notes for S&P 500 Index

U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining around 100 points on Monday.

The Dow traded up 0.26% to 36,341.44 while the NASDAQ rose 0.12% to 14,421.98. The S&amp;P 500 also rose, gaining, 0.30% to 4,618.11.

Nasdaq Edges Higher; Macy&#39;s Shares Jump

Cogent Biosciences Inc

The agreement with ENGIE Resources LLC, which runs through 2033, will begin with six RTX locations in&nbsp;Texas&nbsp;in 2024 and expand to 12 locations by 2028.&nbsp;The agreement will provide more than 1.5 million megawatt hours of renewable electricity over the next 10 years, reducing RTX emissions by an estimated 560,000 metric tons of carbon dioxide

RTX Enters Agreement With Subsidiary Of Engie North America That Will Provide 100% Renewable Electricity To 12 Of Its Texas Facilities

Health Care

General

BLCO

Bausch + Lomb Announced Its ONE By ONE And Biotrue Eye Care Recycling Programs Have Collected 84.3M Units, Or 510,116 Pounds, Of Used Contact Lenses, Eye Care And Lens Care Materials In The U.S.

Richard Philipson, Chief Medical Officer of Calliditas, said,&nbsp;&quot;These additional data further reinforce the impact of Nefecon across the entire study population, irrespective of baseline UPCR levels or patient&#39;s racial and ethnic backgrounds.&quot;

CALT

Calliditas Therapeutics Presents Additional Data Analyses From Phase 3 NeflgArd Trial Of Nefecon In Primary IgA Nephropathy At ISN World Congress Of Nephrology 2024

MediaCo Holding Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDIA#NASDAQ">MDIA</a>) (&quot;MediaCo&quot;) today announced that it has acquired all of Estrella Media&#39;s network, content, digital, and commercial operations. Among the Estrella Media brands joining MediaCo are the EstrellaTV network and its influential linear and digital video content business, and Estrella Media&#39;s expansive digital channels, including its four FAST channels &ndash; EstrellaTV, Estrella News, Cine EstrellaTV, and Estrella Games &ndash; and the EstrellaTV app. The transaction closed on April 17, 2024.

MDIA

MediaCo Acquires Estrella Media's Content and Digital Operations

WIIM

Las Vegas Sands shares are trading lower despite better-than-expected Q1 results.

Keybanc analyst Michael Turits maintains MongoDB (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDB#NASDAQ">MDB</a>) with a Overweight and lowers the price target from $490 to $440.

Price Target

Analyst Ratings

Keybanc Maintains Overweight on MongoDB, Lowers Price Target to $440

The study found that due to the independent and non-bonded internal layers of ALLEVYN LIFE Dressing, a layer-on-layer sliding phenomenon occurs and allows for dissipation of mechanical energy that could otherwise be transferred to the patient in a bonded dressing.1

Smith+Nephew Announces New Evidence Supporting Allevyn Life Foam Dressing's Role In Pressure Injury Prevention

Benitec Biopharma&nbsp;announced a&nbsp;$40.0&nbsp;million&nbsp;private investment in public equity (PIPE) financing from the sale of 5.749 million shares of its common stock at a price per share of&nbsp;$4.80, and, in lieu of shares of common stock,&nbsp;pre-funded&nbsp;warrants to purchase up to an aggregate of 2.58 million shares of its common stock at a price per&nbsp;pre-funded&nbsp;warrant of&nbsp;$4.7999, to certain institutional accredited investors.&nbsp;Gross proceeds from the PIPE financing total approximately&nbsp;$40.0&nbsp;million, before deducting offering expenses.
The Company intends to use the net proceeds from the PIPE financing to fund the clinical development and related commercialization of BB-301, including the natural history lead-in study and the Phase 1b/2a BB-301 treatment study, and for general corporate purposes.

Offerings

BNTC

Benitec Biopharma Reports Oversubscribed Private Placement Financing Of $40M

Longitudinal Study of a 200+ Real-World Patient Cohort Further Validates CCL24 as a Novel Target for Systemic Sclerosis (SSc), Showing that It is Associated with Disease Severity Across the Fibrotic&nbsp;and Vascular Manifestations of SSc

Biotech

Chemomab Therapeutics Ltd. - American Depositary Shares

CMMB

Chemomab Reports New Peer-Reviewed Publication Reinforcing The Clinical Association Of Its CCL24 Target with Disease Severity and Mortality In Systemic Sclerosis

Contracts

Tech

EADSF

European Aeronautic Defence And Space Unsponsored

EADSY

Mobilicom And Airbus Complete Integration And Flight Proof-Of-Concept On Airbus Mid-Sized Jet-UAV For Long-Range Operations

Cyngn Provides Business Update; Says Focused On Opening New Distribution And Sales Channels

BTCY

Biotricity Launches Cardiac Monitoring Pilot Program In A Hospital System Comprised Of 9 Hospitals And 10 Clinics

Lion Electric Announces Workforce Reduction Impacting Approximately 120 Employees, Mainly 'Canada-based employees in overhead and product development functions.'; Says Reduction Should Not Negatively Impact Production Capacity, Will Have ~1,150 Employees Following Reduction

<ul>
<li>Anticipated conventional throughput of 64,000 barrels per day (bpd) exceeding&nbsp;guidance&nbsp;of 60,000 to 63,000 bpd due to stronger capacity utilization compared to forecast;</li>
<li>Strong renewable throughput and utilization in line with midpoint of&nbsp;guidance;</li>
<li>Projected improved average&nbsp;first quarter&nbsp;crack spreads on finished refined products of&nbsp;28%&nbsp;compared to&nbsp;fourth quarter&nbsp;2023; and</li>
<li>Forecasted reductions in direct operating expense by&nbsp;11%&nbsp;and capital expenditures by&nbsp;29%&nbsp;compared to previous&nbsp;guidance&nbsp;midpoints.</li>
</ul>

VNTRD

Vertex Energy Provides Q1 2024 Operational Update

TLSA

Tiziana Life Sciences Announces New Quantitative PET Imaging Data On Foralumab At Meeting Of American Academy of Neurology

The 2025 Toyota Camrys Are Expected To Arrive At Toyota Dealerships In Late Spring 2024 With A Starting Manufacturer's Suggested Retail Price Of $28,400

2024&nbsp;Outlook&nbsp;and Longer-Term&nbsp;Outlook
The Company reiterated its full-year 2024&nbsp;outlook:
<ul>
<li>Total service revenue growth between&nbsp;4%&nbsp;and&nbsp;6%&nbsp;for full-year 2024. Total service revenue for 2023 was&nbsp;$584.5 million.</li>
<li>Full-year 2024 OEBITDA between&nbsp;$460 million&nbsp;and&nbsp;$470 million. OEBITDA for 2023 was&nbsp;$463.1 million.</li>
<li>Cash taxes of less than&nbsp;$10 million&nbsp;per year from 2024 through 2026. We now expect that the longer-term cash tax rate will move closer to the statutory rate in 2028.</li>
<li>Net leverage below 2.5 times OEBITDA as we exit 2026 and falling below 2.0 times OEBITDA by the end of the decade, assuming the completion of the Company&#39;s share repurchase authorization and the payment of quarterly dividends. Net leverage was 3.1 times OEBITDA at&nbsp;December 31, 2023.</li>
</ul>

Guidance

IRDM

Iridium Communications Reiterated FY24 Service Revenue Growth of 4%-6%, OEBITDA of $460M-$470M

Keybanc analyst Michael Turits maintains Palo Alto Networks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PANW#NASDAQ">PANW</a>) with a Overweight and lowers the price target from $380 to $355.

PANW

Keybanc Maintains Overweight on Palo Alto Networks, Lowers Price Target to $355

Genuine Parts Company Raises FY24 Adjusted Diluted EPS Outlook To $9.80-$9.95 From $9.70-$9.90 (Estimate: $9.78); Reaffirms Revenue Growth Of 3% To 5%

ALTR

Altair Acquires Cambridge Semantics; Terms Not Disclosed

Cogent Biosciences stock jumps on Phase 2 data for bezuclastinib

Cogent Biosciences (COGT – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ami Fadia from Ne...

Buy Rating Affirmed for Cogent Biosciences as Bezuclastinib Showcases Strong Market Potential

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Cogent Biosciences (COGT – Research Report), Lantheus (LNTH – Res...

Analysts Offer Insights on Healthcare Companies: Cogent Biosciences (COGT), Lantheus (LNTH) and Ardelyx (ARDX)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Cogent Biosciences (COGT – Research Report) and Moderna (MRNA – R...

Analysts Have Conflicting Sentiments on These Healthcare Companies: Cogent Biosciences (COGT) and Moderna (MRNA)

Cogent Biosciences GAAP EPS of -$0.63

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Cogent Biosciences (COGT – Research Report) and Altimmune (ALT – ...

Analysts Conflicted on These Healthcare Names: Cogent Biosciences (COGT) and Altimmune (ALT)

Cogent downgraded at Baird on rare disease drug data

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Cigna (CI – Research Report), Cogent Biosciences (...

Analysts Offer Insights on Healthcare Companies: Cigna (CI), Cogent Biosciences (COGT) and Canopy Growth (CGC)

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Cogent Biosciences (COGT – Research Report), Celldex...

Analysts Offer Insights on Healthcare Companies: Cogent Biosciences (COGT), Celldex (CLDX) and Laboratory (LH)

Overall market sentiment has been high on Cogent Biosciences Inc (COGT)  stock lately. COGT receives a Bullish rating from InvestorsObserver Stock Sentiment Indicator. Cogent Biosciences Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on COGT!See Full COGT ReportWhat i

Cogent Biosciences Inc (COGT) Stock: What Does the Chart Say Monday?

ARDX

CLDX

LNTH

MRNA

Press Releases

Cogent Biosciences Presents New Preclinical Data Highlighting Potential Best-in-Class Potency and Selectivity of ErbB2 and PI3Kα inhibitor programs at the San Antonio Breast Cancer Symposium

Cogent Biosciences Announces Positive Initial Data from Phase 2 SUMMIT Trial Evaluating Bezuclastinib in Patients with Nonadvanced Systemic Mastocytosis (NonAdvSM)

Cogent Biosciences Announces Positive Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)

Cogent Biosciences Announces Presentation at the 42nd Annual J.P. Morgan Healthcare Conference

Cogent Biosciences Announces Planned 2024 Milestones for Bezuclastinib and Emerging Portfolio of Selective and Potent Targeted Therapeutics

Cogent Biosciences to Present SUMMIT Part 1b Data with Bezuclastinib in NonAdvanced Systemic Mastocytosis (NonAdvSM) at the 2024 AAAAI Annual Meeting

Cogent Biosciences Announces Oversubscribed $225 Million Private Placement

Cogent Biosciences Announces Positive Part 1b Data from SUMMIT Trial Evaluating Bezuclastinib in Patients with Nonadvanced Systemic Mastocytosis

Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results

Cogent Biosciences Presents Data Highlighting Potential Best-in-Class Potency and Selectivity of Novel, EGFR Sparing, CNS-Penetrant ErbB2 Inhibitor